# TriGemX Bio Announces $600M Public Listing

> TriGemX Bio to go public with $600 million valuation after business combination with TCGX Acquisition Corp.
- Title: TriGemX Bio Announces $600M Public Listing · TokenPost
- Summary: TriGemX Bio to go public with $600 million valuation after business combination with TCGX Acquisition Corp. TriGemX Bio and TCGX Acquisition Corp. agreed to…
- Keywords: trigemx bio, tcgx acquisition corp, nasdaq, tgem, migraine drug, elismetrep, phase 3 trials, fda, crypto, finance, TriGemX, Bio
- Source: TokenPost — https://tokenpost.com/news/business/34770
- Published: 2026-10-19T12:29:33+00:00
- Read time: 1 min
- Topics: trigemx bio, tcgx acquisition corp, nasdaq, tgem, migraine drug, elismetrep, phase 3 trials, fda, crypto, finance
## Business Combination Agreement
TriGemX Bio and TCGX Acquisition Corp. announced a definitive business combination agreement on Oct. 19 for a projected $600 million equity value.
## Projected Financials
The transaction generates $246 million in gross proceeds before costs, including $86 million from TCGX's trust account and $160 million from private equity at $10 per share.
## Next Steps for Migraine Drug
If the deal closes, the company will fund Phase 3 trials for elismetrep, submit a New Drug Application, and prepare for a potential U.S. launch by mid-2027.
## Key takeaway

TriGemX Bio and TCGX Acquisition Corp. agreed to a business combination valued at $600 million, with the combined company expected to trade on Nasdaq as TGEM.